Albireo Pharma Profit Margin

The latest profit margin for ALBO is -228.51% as of September 2022. That compares with -444.28% in the prior-year period — up 48.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Albireo Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALBO's profit margin moved from -444.28% to -228.51% — a 48.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Albireo Pharma's valuation or profitability profile.

Against Healthcare companies, ALBO currently prints -228.51% for profit margin, while the sector average sits near 13.89%. That is roughly 1745.7% below the sector mean. Large gaps often invite a closer look at Albireo Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Albireo Pharma converts resources into returns. At -228.51%, ALBO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -444.28% in the prior-year period — up 48.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALBO's profit margin (-228.51%), review year-over-year change from -444.28%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.